Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Download Data

Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023

Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR is NA for the Trailing 12 Months (TTM) ending September 30, 2023. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2023 was -30,148,597.37, a -94.22% change year over year.
Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2022 was -15,522,761.39, a -55.82% change year over year.
Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2021 was -9,961,926.11, a -17.53% change year over year.
Tenaya Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2020 was -8,475,765.33.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends